PDF《药源快讯》

1、 (i)Margolin K, Ernstoff MS, Hamid O, et al. Ipili- mumab in patients with melanoma and brain metastases: an open-label, phase

2 trial. Lancet Oncol 2012;

13:459-465. (ii) Weber JS, Kahler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J Clin Oncol 2012. (iii) Hodi FS, O'

Day SJ, McDermott DF, Weber RW, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010;

363:711-723. (iv) Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;

364:2517-2526.

2、 (i)Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemu- rafenib. N Engl J Med 2012;

366:707-714. (ii) Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;

2507-2516.

3、 Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open- label, phase

3 randomised controlled trial. Lancet 2012;

380:358-365.

4、 Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Muta- tions. N Eng J Med 2012;

367:1694-1703.

5、 (i) Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of

283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus in- terleukin 2. JAMA 1994;

271:907-913. (ii) Atkins MB, Lot- ze MT, Dutcher JP, et al. High-dose recombinant inter- leukin

2 therapy for patients with metastatic melanoma: analysis of

270 patients treated between

1985 and 1993. J Clin Oncol 1999;

17:2105-2116. (i........